We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
Read MoreHide Full Article
Infinity Pharma announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were up almost 9% on Jul 10, following the news.
Eganelisib is an immuno-oncology macrophage reprogramming drug candidate.
The MARIO-8 study aims to optimize the dose of eganelisib in combination with the standard dose of Merck’s (MRK - Free Report) Keytruda (pembrolizumab). It will be conducted in two parts.
Part A will be a dose optimization study, wherein 30-mg and 20-mg dose regimens of eganelisib will be evaluated. The company has received feedback from the FDA regarding the study's plan. It expects to get initial safety and effectiveness data by the second half of 2024 after the FDA reviews it and the merger with MEI Pharma (MEIP - Free Report) is finalized.
Once the best dose in Part A is determined, Part B of the study will involve around 100 additional patients. The primary endpoint of the phase II study will be overall survival, with secondary endpoints including progression-free survival and safety.
Infinity Pharma’s shares have nosedived 57.7% year to date compared with the industry’s 3.2% decline.
Image Source: Zacks Investment Research
In February, INFI and MEI Pharma entered into a definitive merger agreement to combine their resources and expertise in oncology drug development. The merger aims to create a company with a strong pipeline of three clinical-stage oncology drug candidates.
These candidates are eganelisib, voruciclib and ME-344, which are being evaluated as combination therapy for different cancer indications.
Merck’s Keytruda is already approved for the treatment of many cancers globally. Keytruda sales are gaining from continued strong momentum in metastatic indications, including renal cell carcinoma and SCCHN, as well as a rapid uptake across recent earlier-stage launches.
The drug is continuously growing and expanding into new indications and markets globally. In the first quarter of 2023, Merck recorded revenues of $5.8 billion from Keytruda product sales.
Infinity Pharmaceuticals, Inc. Price and Consensus
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss of $2.92 per share to a loss of $2.80 for 2023 in the past 90 days. The company's shares have nosedived 17.9% year to date.
AKRO’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
Infinity Pharma announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were up almost 9% on Jul 10, following the news.
Eganelisib is an immuno-oncology macrophage reprogramming drug candidate.
The MARIO-8 study aims to optimize the dose of eganelisib in combination with the standard dose of Merck’s (MRK - Free Report) Keytruda (pembrolizumab). It will be conducted in two parts.
Part A will be a dose optimization study, wherein 30-mg and 20-mg dose regimens of eganelisib will be evaluated. The company has received feedback from the FDA regarding the study's plan. It expects to get initial safety and effectiveness data by the second half of 2024 after the FDA reviews it and the merger with MEI Pharma (MEIP - Free Report) is finalized.
Once the best dose in Part A is determined, Part B of the study will involve around 100 additional patients. The primary endpoint of the phase II study will be overall survival, with secondary endpoints including progression-free survival and safety.
Infinity Pharma’s shares have nosedived 57.7% year to date compared with the industry’s 3.2% decline.
Image Source: Zacks Investment Research
In February, INFI and MEI Pharma entered into a definitive merger agreement to combine their resources and expertise in oncology drug development. The merger aims to create a company with a strong pipeline of three clinical-stage oncology drug candidates.
These candidates are eganelisib, voruciclib and ME-344, which are being evaluated as combination therapy for different cancer indications.
Merck’s Keytruda is already approved for the treatment of many cancers globally. Keytruda sales are gaining from continued strong momentum in metastatic indications, including renal cell carcinoma and SCCHN, as well as a rapid uptake across recent earlier-stage launches.
The drug is continuously growing and expanding into new indications and markets globally. In the first quarter of 2023, Merck recorded revenues of $5.8 billion from Keytruda product sales.
Infinity Pharmaceuticals, Inc. Price and Consensus
Infinity Pharmaceuticals, Inc. price-consensus-chart | Infinity Pharmaceuticals, Inc. Quote
Zacks Rank & Stock to Consider
Infinity Pharma currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the overall healthcare sector is Akero Therapeutics (AKRO - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss of $2.92 per share to a loss of $2.80 for 2023 in the past 90 days. The company's shares have nosedived 17.9% year to date.
AKRO’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.